A new study showed that the medicine “Likanimab” for the treatment of Alzheimer’s is very safe, beyond the conditions of clinical trials, especially when used in the early stages of the disease. The US Food and Drug Administration (FDA) agreed to use treatment a year ago, but this caused a lot of controversy as a result of its side effects. The study, published in the magazine “The American Medical Association for Neuroscience”, relied on the review of the data of 234 patients who received the ‘Likanimab’ treatment in memory diagnostic center of the Faculty of Medicine at the University of Washington in Saint -Lewis. She indicated that the serious side effects were scarce and medical handling, as the cases required by hospitalization were not just 1%. Alzheimer’s therapy is the first treatment of Likanimab, the first treatment that slows down the development of Alzheimer’s by targeting amyloid plaques in the brain. According to the researchers, people who were at a very early stage of the disease – at very mild symptoms – were least exposed to complications, as 1.8% of this category suffered from side effects, compared to 27% of patients in the next phase of the disease. The author, Parra Joy Sinider, Professor of Neurological Medicine, said that the fear of complications – such as swelling or cerebral bleeding associated with the so -called “mill -associated moders” – may force some to delay the treatment, which later increases the possibility of these complications. She emphasized that the study shows the ability of specialized outpatient clinics to effectively deal with these effects, paving the way for expanding the use of treatment in other centers. ‘Considerative results’ are given the treatment of ‘lyanimab’ in the form of intravenous injection every two weeks, and patients undergo regular brain imaging contrasts to monitor any changes. In rare cases, the dose is suspended or steroidal therapy is performed when severe symptoms occur. According to the study, no deaths were recorded among patients who received treatment in the center, and most cases in which side effects emerged were restored within months. The author, Susan Shendler, said: “Most patients respond well to the middle. The results are reassuring and help to reformulate the dialogue between doctors and patients about the benefits and risks of treatment, especially in the early stages of Alzheimer’s, where the chances of success are greater and the risks are less.” Likanimab is a mono -tissible antibody designed to target beta -amyloid plaques in the brain, which is one of the most important causes of the development of Alzheimer’s disease. The monochrome antibody is a special type of antibodies produced in the laboratory to target a specific substance in the body with great accuracy, such as a specific protein on the surface of a cell, virus or beta-amyloid protein associated with Alzheimer’s disease, as in the case of “Likanimab”. The word “one -sided” means that it is the result of one cell, or from it cloning, that is, it is a duplicate of one antibody, and that all the antibodies produced are identical to form and function, and target exactly the same purpose. Clinical experiments have shown that ‘Likanimab’ manages to delay the cognitive decline by 27% after 18 months of treatment, compared to patients who have received a false medicine. This effect may look minor on paper, but it means extra months of independence for the injured before they care daily, which is an important profit in the context of an irreplaceable disease. Likanimab is used only in early cases of Alzheimer’s, that is, for those suffering from simple cognitive disability, or light dementia, not for medium or advanced conditions. It is also necessary for the patient to have a certain accumulation of amyloid protein, and it can be verified by advanced tests such as MRI, or cerebrospinal fluid tests. Side effects and despite the effectiveness of the medication, the side effects cannot be ignored, and the most dangerous of which is known as the changes associated with amydied in brain images, which include swelling or minor bleeding in the brain. In most cases, symptoms do not occur in the patient, and changes are only discovered in routine graphic tests, but in rare cases the patient may suffer from headaches, dizziness, nausea or even attacks. The data of the third phase experience showed that 12.6%of patients were injured in this condition, but the severe symptoms were very rare (about 2.8%), and the percentage of deaths directly associated with the middle was only 0.2%. The price of the drug received the ‘Likanimab’ medicine approval from the US Food and Drug Administration in 2023, first via the accelerated road, and then with traditional approval later. It was also approved by countries such as Japan, South Korea, Mexico and Britain, while Australia rejected it in principle, before confirming its final rejection in March 2025. In Europe, the approval came after a controversy over the effectiveness of the risks, and the use was limited on the basis of the genetic analysis of the patient. The annual treatment price is Bleakimab $ 26500, which has aroused criticism about “the value of the drug for its price”. Some parties see that the fair price should vary between $ 8900 and 21,500. The producing enterprise estimates that about 85% of US patients who are qualified for treatment are covered by insurance, which can reduce the financial burden on individuals, but this puts the budgets of the public health sector under pressure.
Study: a cure for the treatment of Alzheimer’s disease that proves its effectiveness after it is clinical
